Zacks Investment Research · Nov 1, 2023
United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates
United Therapeutics (UTHR) third-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.
MI
NASDAQ · MIRO
Miromatrix Medical Inc.
Healthcare · Biotechnology
$3.39
Up+$0.02 (+0.59%)
Updated Sep 12, 2026, 8:43 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 92.95M
- P/E ratio
- -2.34
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 631.56K
- Avg. volume
- 189.88K
Price performance
MIRO price history
1M range · 0 trading sessions · Daily adjusted prices
MIRO does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest MIRO news
The latest Smart Investors Daily articles mentioning MIRO.
Stock researchCompany · Overview
MIRO research
Overview
Company profile and research snapshot.
Company profile
Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. The company has collaborations with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $9.00
- Implied upside
- —
- Analysts
- 8
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 12, 2023 | Piper Sandler | Overweight | — |
| Apr 3, 2023 | Piper Sandler | Overweight | — |
| Nov 15, 2022 | Piper Sandler | Overweight | — |
| Aug 31, 2022 | Piper Sandler | Overweight | — |
| Jul 19, 2021 | Craig-Hallum | Buy | — |
News briefing
No generated briefing is available yet.
GlobeNewswire Inc. · Oct 30, 2023
United Therapeutics to Acquire Miromatrix Medical
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. and EDEN PRAIRIE, Minn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today a definitive agreement for United Therapeutics to acquire Miromatrix.
GlobeNewswire Inc. · Oct 11, 2023
Miromatrix to Present at the 2023 ISODP Organ Donation Congress
EDEN PRAIRIE, Minn., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that it will be presenting at the 2023 International Society for Organ Donation and Procurement ("ISODP") Organ Donation Congress in Las Vegas, NV on October 18-21 at Mandalay Bay Resort.
GlobeNewswire Inc. · Oct 5, 2023
Miromatrix CEO Jeff Ross to Present at the 2023 Cell & Gene Meeting on the Mesa
EDEN PRAIRIE, Minn., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that CEO Jeff Ross will present at the 2023 Cell & Gene Meeting on the Mesa in Carlsbad, CA. The three-day event, held this year on October 10-12, will feature presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
